14 February 2023 in Acta Neuropathologica
5 December 2025 in JID Innovations
Whole-genome sequencing can uncover clinically significant noncoding variants missed by standard germline testing, as demonstrated in this report in a patient with Muir–Torre syndrome, a subtype of Lynch syndrome. In this case, despite a convincing clinical phenotype and immunohistochemical loss of MSH2/MSH6 in 1 of the patient’s tumors, conventional gene panel testing failed to detect a germline pathogenic variant. Whole-genome sequencing identified a deep intronic MSH2 variant, and tumor sequencing revealed somatic MSH2 mutations (second hits) across multiple tumors, confirming mismatch repair deficiency and establishing a Muir-Torre syndrome diagnosis. This report underscores the limitations of routine genetic testing and highlights the clinical utility of whole-genome sequencing in identifying pathogenic variants in noncoding regions. It also emphasizes the role of dermatologists in recognizing cutaneous markers of hereditary cancer syndromes and the importance of interdisciplinary evaluation in guiding both patient care and familial risk assessment.
22 August 2025 in The Journal of Pathology
Attenuated familial adenomatous polyposis (AFAP) is a disorder caused by germline pathogenic variants in APC and is characterized by the presence of <100 colonic polyps and a high lifetime risk of developing colorectal cancer. Salivary gland basal cell tumours are uncommon and have not previously been reported in AFAP. We present a family with AFAP and multiple salivary gland tumours, including basal cell adenoma (BCA) and basal cell adenocarcinoma (BCAC). The colon and salivary gland tumours showed abnormal nuclear β‐catenin staining. Genomic analysis of both parotid BCACs showed copy‐number‐neutral loss of heterozygosity (CNN‐LOH) at the APC locus, implicating loss of full‐length APC in the aetiology of parotid BCACs. In contrast, the submandibular BCAC showed a p.(Ile35Thr) CTNNB1 mutation. Spatial transcriptomic analysis revealed a stepwise increase in the expression of WNT pathway genes across the proband's salivary lesions, from benign (intercalated duct hyperplasia and BCAs) to malignant (BCACs). Our results showcase BCA and BCAC as potential new phenotypes of AFAP. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
2 May 2024 in Cancer Prevention Research
Improved cancer screening and treatment programs have led to an increased survivorship of patients with cancer, but consequently also to the rise in number of individuals with multiple primary tumors (MPT). Germline testing is the first approach investigating the cause of MPT, as a positive result provides a diagnosis and proper clinical management to the affected individual and their family. Negative or inconclusive genetic results could suggest non-genetic causes, but are negative genetic results truly negative? Herein, we discuss the potential sources of missed genetic causes and highlight the trove of knowledge MPT can provide. See related article by Borja et al., p. 209
5 October 2022 in Research Square
Background Schwannomatosis is a disorder characterized by a predisposition to multiple benign spinal, peripheral and intracranial nerve sheath tumors (schwannomas (SWNs)). The molecular mechanism of schwannomatosis involves several genes located on chromosome 22q, SMARCB1, LZTR1, NF2 and more recently, DGCR8. Case Presentation: here, we present a family with SMARCA4-associated schwannomatosis - this is the first report of this association. The proband presented with a spinal SWN at age 30y whilst her mother (deceased) had had 4 peripheral SWNs (right and left arms) at age 50y followed by a glioblastoma (GBM) at age 54y. All the tumors, except for the GBM, showed loss of BRG1 (SMARCA4) in 80–90% of cells and loss of INI1 (SMARCB1) in the complementary 10–20% of cells. The GBM showed retention of BRG1 and INI1. Whole exome sequencing of the proband’s germline revealed a likely pathogenic (LP) variant, SMARCA4 (NM_001128844.2):c.1752_1755del, p.(Lys585Argfs*27) (ClinVar ID: 873514). Furthermore, we identified LOH at the SMARCA4 locus along with 12–23 Mb of chromosome 19p in all SWNs (acting as the second hits), but not in the GBM. No other pathogenic variants or allelic imbalance on Chromosome 22q were detected in the schwannomas. Additionally, from DNA methylation analyses, we observed that the SMARCA4- associated SWNs clustered together with other SWNs (mutated in SMARCB1 or LZTR1, or negative germline status) and away from rhabdoid tumours associated with SMARCA4 and SMARCB1 deficiency (small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) and atypical teratoid rhabdoid tumour (ATRT)). Conclusion Taken together, our findings lead us to propose SMARCA4 as a new candidate schwannomatosis gene and that there might be other mechanisms by which SWNs are formed.
24 September 2025 in Research Square
Hereditary breast cancer involves multiple risk genes, including BARD1, which confers low to moderate risk and is associated with triple-negative breast cancer (TNBC). We report a proband with a primary ER+/PR+/HER2- breast cancer which recurred unilaterally as a TNBC and who later developed endometrial cancer. Clinical germline testing revealed a rare BARD1 missense variant of uncertain significance [c.2258G > T; p.(Gly753Val)]. Whole-exome sequencing of tumors and blood revealed BARD1 loss of heterozygosity and mutational signature 3 – indicative of homologous recombination (HR) repair deficiency – exclusively in the TNBC recurrence. Functional assays demonstrated impaired HR repair via increased PARP inhibitor sensitivity and reduced RAD51 foci formation. We hypothesize that the selective pressure exerted by tamoxifen resulted in breast cancer subtype switching and uncovered the pathogenic potential of the BARD1 p.(Gly753Val) variant. This case illustrates a previously unreported scenario where the pathogenicity of a germline BARD1 variant appears conditional on prior treatment.